Evidence map›Paper›PMID 29156205›Full record

ReviewBest practice & research. Clinical haematology2017

Which factors influence the development of GVHD in HLA-matched or mismatched transplants?

Effie W Petersdorf

Abstract readReview
In one paragraph

Review in Best practice & research. Clinical haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Effie W PetersdorfUniversity of Washington School of Medicine, 1959 NE Pacific St., Seattle, WA 98195, USA; Fred Hutchinson Cancer Research Center, Division of Clinical Research, 1100 Fairview Ave North, Seattle, WA 98109, USA. Electronic address: epetersd@fredhutch.org.

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4M
Hematopopietic Stem Cell TransplantationU01AI069197 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Effie W Petersdorf · 2005 to 2026
$18.9M
Clinical Significance of MHC Haplotypes in Hematopoietic Cell TransplantationR01CA100019 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERSDORF, EFFIE W · 2003 to 2025
$9.1M
Genetic Mechanisms of Survivorship Disparities after Unrelated HCTU01CA162194 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETERSDORF, EFFIE W · 2011 to 2015
$1.7M
NCI NIH HHS P01 CA018029NCI NIH HHS R01 CA100019NCI NIH HHS U01 CA162194NIAID NIH HHS U01 AI069197
6 · The paper itself

Abstract

The sheer diversity of HLA alleles makes the probability of finding matched unrelated donors for patients requiring hematopoietic cell transplantation (HCT) a complex situation. New evidence suggests that mismatching at certain HLA loci may provide a greater benefit in terms of graft-versus-leukemia effect than other mismatches when HLA-matched donors are not available. This review summarizes the current understanding of HLA matching requirements for unrelated donor HCT.

Indexed as

AllelesHematopoietic Stem Cell TransplantationHistocompatibility TestingUnrelated DonorsGraft vs Host DiseaseGraft vs Leukemia EffectHLA AntigensHumansHLA AntigensAlleleGraft-versus-host diseaseGraft versus leukemiaGVHDGVLHCTHematopoietic cell transplantationHLAMatchedMismatched

Identifiers

PMID29156205
PMCPMC5967625

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.